The fibromyalgia syndrome (FMS) is considered to result from the exposure of a genetically susceptible individual to various triggers, such as physical trauma, stress, viral infections etc. A possible role of vaccination in FMS etiology has been suspected. Our objective was to evaluate the efficacy and safety of influenza vaccination in FMS patients. Nineteen FMS patients underwent physical and dolorimetric examinations and answered the fibromyalgia impact questionnaire (FIQ), the widespread pain index (WPI) checklist and the symptoms severity scale (SSS), which are part of the 2010 diagnostic criteria. Thirty-eight healthy subjects were recruited as controls. All participants were vaccinated with the inactivated split virion influenza vaccine. Serum was collected for antibody titration. Six weeks after vaccination, sera were tested by hemagglutination (HI) against A/California (H1N1), A/Perth (H3N2) and B/Brisbane. Humoral response was defined as either a fourfold or greater increase in titer, or an increase from a non-protective baseline level of <1/40 to a level of 1/40. No severe vaccination reactions were observed. No significant change was observed between WPI, SSS and FIQ values before and after vaccination, indicating no worsening of FMS symptoms. Vaccine immunogenicity: Six weeks after vaccination, FMS patients showed a significant increase in geometric mean titers of HI antibody. The rates of sero-protection increased from 22.9% for H1N1 to 89.5% post-vaccination. A significant increase in HI antibody titers was also demonstrated among healthy controls. Influenza vaccination was both safe and effective in FMS patients. In view of these results, FMS patients should be encouraged to undergo influenza vaccination according to the standard WHO recommendations.
n INTRODUCTION F ibromyalgia is a clinical syndrome characterized by chronic widespread pain with tenderness and fatigue. Central sensitization is considered a major pathogenic feature of the fi bromyalgia syndrome (FMS) (1). While the etiology of FMS is not yet completely understood, it is generally considered to result from the interaction between a specifi c genetic background and word the exposure of a susceptible individual to various enhancing triggers, such as physical trauma, infection, stress, etc. (2). The potential role of vaccination in causing or exacerbating FMS had already been suspected in the past (3, 4). In view of this background it is of considerable clinical importance to ascertain both the efficacy and safety of vaccination in patients suffering from FMS. Our group has previously established that infl uenza vaccination is safe and effective in rheumatoid arthritis patients (5). Therefore, the aim of this study was to ascertain its effi cacy and safety in patients suffering from FMS. prior diagnosis of fibromyalgia, age over 18 and ability to give informed consent. Exclusion criteria were a known allergy to egg products or influenza vaccine, a febrile disease in progress and pregnancy. Each patient reported his/her complete history including the use of medications, and underwent physical examination and dolorimetry before undergoing vaccination. The fulfillment of the American College of Rheumatology (ACR) 1990 FMS classification criteria was duly documented (6) . Patients filled in the widespread pain index (WPI) checklist and the symptoms severity scale (SSS), derived from the 2010-2011 ACR preliminary diagnostic criteria for FMS (7, 8) and the Hebrew version of the fibromyalgia impact questionnaire (FIQ) (9) . Healthy controls (38) were recruited from the hospital staff. The study was approved by the institutional ethics committee and all patients gave a written informed consent. Participants were vaccinated with the inactivated split virion influenza vaccine, recommended by the WHO and serum samples were collected for antibody titration. Six weeks after vaccination, patients were evaluated again and serum was collected for the second time. Patients were also asked whether they developed any direct vaccine-related side effects and how were their general health conditions following vaccination.
Immunogenicity of the vaccine
The pre-and post-immunization hemagglutination (HI) antibodies were tested at the Central Virology Laboratory of the Israeli Ministry of Health using the HI test according to the standard WHO procedure (10) . Sera were tested by HI test against the three antigens included in the vaccine: A/ California (H1N1), A/Perth (H3N2) and B/Brisbane. Sera were separated, code labeled, and stored at -20°C until the test was conducted. They were treated with receptor-destroying enzyme cholera filtrate to remove non-specific inhibitors, and with Turkey red blood cells to remove non-specific agglutinins. The treated sera were tested by an HI test against the three antigens included in the vaccine: A/ California (H1N1), A/Perth (H3N2) and B/ Brisbane. The effective dilution (test dose) of each antigen contained 4 HA units in 25 mL of antigen. Test doses were diluted in phosphate-buffered saline and added to serial dilutions of anti-serum. The HA inhibition titer was determined as the highest dilution of serum that inhibited completely the hemagglutination of red blood cells. Humoral response was defined as either a fourfold or greater increase in titer, or a rise from a non-protective baseline level of <1/40 to 1/40 after vaccination. The titer of an antiserum that did not show any inhibition was recorded as 1/10. Geometric mean titers of antibodies were calculated to assess the entire group immunity.
Statistical methods
Non-parametric tests were used in the analysis, since most parameters were not normally distributed. In addition, parametric tests were performed for the log transformation of the parameters. The statistical analysis was performed using the SPSS system for Windows, release 17.0.
n RESULTS
No severe vaccination-related events were documented among patients or controls enrolled in this study.
Characteristics of patients and controls
Nineteen FMS patients and 38 healthy controls were recruited. Sixteen out of nineteen patients (84.2%) were female and their mean age was 46.6 years.
Effect of vaccination against influenza on disease activity
Vaccination against influenza was not associated with a significant worsening of any clinical index of disease activity ( 
n DISCUSSION
This study has demonstrated that influenza vaccinations are both safe and effective in patients suffering from fibromyalgia. This conclusion is of significant practical importance for health care providers who need to inform their FMS patients about risks and benefits of vaccination.
As noted above, the potential link between FMS and prior exposure to vaccines is an issue which has raised significant interest and debate in the literature. Not only was this discussion focused on fibromyalgia per se, but also on the broader field of central-sensitization-related conditions as well as other multi-system and enigmatic conditions. For instance, the Gulf war syndrome, an entity with considerable clinical overlap with FMS, was considered to be potentially linked with exposure to multiple vaccinations (11, 12) . More recently, a theory has been proposed regarding the possibility that vaccination-related adjuvants may induce a multi-system disorder named autoimmune syndrome induced by adjuvants (ASIA), characterized by symptoms such as fatigue, cognitive impairment and arthragia (13, 14) . Both the ASIA syndrome and FMS have recently been reported to be associated with hepatitis B vaccination (15) . Moreover, the Gulf war syndrome was also suggested to be a particular type of this syndrome (16) . The chronic fatigue syndrome (CFS), another condition with considerable overlap with FMS, was also linked with vaccination in the past (17) . The postural orthostatic tachycardia syndrome, another clinical entity which overlaps CFS, has also recently been noted in association with vaccination (18) . However, as previously mentioned, infections per se are considered one of the potential etiological triggers for the development of FMS (19) (20) (21) (22) 
